Pathologist onsite cuts repeat thyroid biopsies
Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.
Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.
University of North Carolina researchers compared 200 biopsies performed with a pathologist onsite and 200 with no pathologist present. All other factors being equal, 13.5% of biopsies performed without a pathologist onsite needed to be repeated, compared with only 5% where a pathologist was onsite, according to the research.
An inadequate sample is one where the pathologist deems there is an insufficient amount of tissue to make a diagnosis.
“We recommend that radiologists performing large numbers of thyroid biopsies use onsite pathology as it may reduce the need for repeat biopsy by up to 60%,” said Dr. Wui K. Chong, lead author of the study and an associate professor of radiology at UNC.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
